Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Linda Pudelko
Observed names:
L. Pudelko,
L.A. Pudelko
Institution:
Merck Healthcare KGaA, Darmstadt (Germany)
Observed institutions:
Merck KGaA, Darmstadt (Germany),
Science for Life Laboratory,
Karolinska Institutet,
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol,
Merck Healthcare KGaA, Darmstadt (Germany)
ORCID:
0009-0007-2201-6475
Observed ORCID:
0009-0007-2201-6475
OpenAlex ID:
A5028192514
Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress
2022
·
Nadilly Bonagas
, Nina M. S. Gustafsson
, et al.
·
Nature Cancer
·
113
PDF
An orthotopic glioblastoma animal model suitable for high-throughput screenings
2018
·
Linda Pudelko
, Steven Edwards
, et al.
·
Neuro-Oncology
·
59
Hypoxic Signaling and the Cellular Redox Tumor Environment Determine Sensitivity to MTH1 Inhibition
2016
·
Lars Bräutigam
, Linda Pudelko
, et al.
·
Cancer Research
·
57
Glioblastoma and glioblastoma stem cells are dependent on functional MTH1
2017
·
Linda Pudelko
, Pegah Rouhi
, et al.
·
Oncotarget
·
44
PDF
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
2020
·
Linda Pudelko
, Frank Jaehrling
, et al.
·
iScience
·
23
PDF
Development of a chemical probe against NUDT15
2020
·
Si Min Zhang
, Matthieu Desroses
, et al.
·
Nature Chemical Biology
·
23
AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
2020
·
Ishani Das
, Helge Gad
, et al.
·
Cell Death and Differentiation
·
23
PDF
MTH1 promotes mitotic progression to avoid oxidative DNA damage in cancer cells
2019
·
Helge Gad
, Oliver Mortusewicz
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
21
PDF
Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic Taoism
2021
·
Christina Wilms
, Klaudia Lepka
, et al.
·
Redox Biology
·
15
PDF
A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
2023
·
Michael A. Carducci
, Ding Wang
, et al.
·
Cancer Research Communications
·
9
PDF
Fishing for cures : the zebrafish as a powerful tool to identify novel therapies against glioblastoma by targeting MTH1 and beyond
2018
·
Linda Pudelko
·
Figshare
·
4
First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors
2026
·
L.L. Siu
, M.E. Gutierrez
, et al.
·
ESMO Open
·
3
104TiP Phase Ib/IIa study of ATR inhibitor tuvusertib + anti-PD-1 cemiplimab in patients with advanced non-squamous (nsq) non-small cell lung cancer (NSCLC) that has progressed on prior anti-PD-(L)1 and platinum-based therapies
2024
·
L. Paz-Ares
, F. Cappuzzo
, et al.
·
ESMO Open
·
3
Supplementary methods for "Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress"
2022
·
Nadilly Bonagas
, Nina Gustafsson
, et al.
·
Research Square
·
2
PDF
1180 Effects of MTH1 inhibitor TH1579 on cutaneous melanoma
2018
·
I. Das
, H. Gad
, et al.
·
Journal of Investigative Dermatology
·
2
PDF
Abstract 3774: Unraveling mechanisms of resistance to tepotinib and future treatment options
2020
·
Linda Pudelko
, Frank Jaehrling
, et al.
·
Cancer Research
·
1
Abstract 105: MTH1 promotes mitotic progression to avoid oxidative DNA damage in cancer cells
2019
·
Kumar Sanjiv
, Helge gad
, et al.
·
Tumor Biology
·
1
Abstract 105: MTH1 promotes mitotic progression to avoid oxidative DNA damage in cancer cells
2019
·
Kumar Sanjiv
, Helge gad
, et al.
·
Cancer Research
·
1
EP.12H.09 Phase 1b/2a Study of ATR Inhibitor Tuvusertib + Anti-PD-1 Cemiplimab in Patients with Advanced Non-Squamous NSCLC
2024
·
N. Vokes
, L. Paz-Ares
, et al.
·
Journal of Thoracic Oncology
PDF
TABLE 3 from A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
2023
·
Michael A. Carducci
, Ding Wang
, et al.
FIGURE 3 from A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
2023
·
Michael A. Carducci
, Ding Wang
, et al.
FIGURE 2 from A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
2023
·
Michael A. Carducci
, Ding Wang
, et al.
TABLE 4 from A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
2023
·
Michael A. Carducci
, Ding Wang
, et al.
TABLE 1 from A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
2023
·
Michael A. Carducci
, Ding Wang
, et al.
TABLE 2 from A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
2023
·
Michael A. Carducci
, Ding Wang
, et al.
Show more works
View as search
Works count:
39
Citation count:
404
H-index:
9
I10-index:
9
Year
Topic
Type